This year’s International Cancer Cluster Showcase featured 20 emerging oncology companies that presented their recent innovations, partnering and investment opportunities.

The International Cancer Cluster Showcase (ICCS) is a satellite event to BIO International Convention and was arranged on 5 June 2023 in Boston, USA. This was the 12th edition of the ICCS and this year the event returned to Boston where this format was started.

The event connects emerging oncology companies from different innovation hubs with potential partners from the global oncology community gathering at BIO. The 20 featured companies were selected by innovation hubs in the United States (Massachusetts & Philadelphia), Quebec, Norway, the UK Golden Triangle, Switzerland, France, and Taiwan, reports Oslo Cancer Cluster.

For those searching for collaboration, partnering and investment opportunities ICCS is an efficient format to meet 20 companies from international hubs and learn about their latest science, technologies, and (mostly preclinical) assets.”

“BIO International Convention is one of the largest gatherings of biotechnology and life sciences professionals from around the world. It provides an excellent platform for companies to network with potential partners, investors, customers, and collaborators. Via being part of the ICCS program emerging oncology companies get special visibility and exposure at the start of BIO. For those searching for collaboration, partnering and investment opportunities ICCS is an efficient format to meet 20 companies from international hubs and learn about their latest science, technologies, and (mostly preclinical) assets,” commented Jutta Heix, Head of International Affairs, Oslo Cancer Cluster and coordinator of the ICCS programme.

3 promising Norwegian companies

NaDeNo, Hemispherian and One-Carbon Therapeutics represented the Nordic region during the event, which included four-minute pitches from each company.

NaDeNo, Hemispherian and One-Carbon Therapeutics represented the Nordic region.”

“Attending the BIO International conference for the first time as a small Norwegian start-up we highly appreciated the opportunity to share our story to a larger audience! Being visible in this way accelerates new relationships and valuable networking, and it really kick-started the conference for us. Many thanks to OCC for giving us this opportunity,” said Annbjørg Falck, CEO and co-founder of NaDeNo.

“The International Cancer Cluster Showcase presents a tremendous opportunity for Hemispherian to showcase our pharmaceutical development program on a global stage. This international exposure serves to highlight the exceptional nature of our technology and the expertise of our team. We are thrilled to have the privilege of presenting alongside other outstanding companies, which also provides us with a platform to showcase the rapidly growing Norwegian biotechnology sector. The event allows us to further establish Hemispherian’s reputation, attract attention to our innovative approach, and foster collaborations in the fight against cancer,” said Adam Robertson, CEO of Hemispherian.

Source: Sofia Lindén/Oslo Cancer Cluster 

Featured image: Annbjørg Falck presented the Norwegian company NaDeNo during the International Cancer Cluster Showcase 2023. Photo: Oslo Cancer Cluster